查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1223358

流感治療的全球市場:各類型，各藥物，各給藥途徑，各流通管道，各終端用戶地區展望，競爭策略，市場區隔預測(～2032年)

Flu Treatment Market Size- By Types, By Medication, By Route of Administration, By Distribution Channel, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2032
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 255 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球流感治療的市場規模，預計到2032年以5.25％的CAGR成長，達到17億4,000萬美元。技術的持續性進步，對流感治療的民營企業和政府機關的夥伴關係，醫療費增加，抗病毒藥物的研究開發費增加，促進市場成長。

本報告提供全球流感治療市場相關調查分析，市場動態，市場分析，企業簡介等系統性資訊。

目錄

第1章 簡介

  • 調查範圍
  • 市場區隔分析

第2章 調查手法

  • 調查資料來源
    • 二次資料
    • 一次資料
    • SPER內部資料庫
    • KOL的洞察
  • 市場規模的估計
    • Top-Down(由上而下)和Bottom-Up(由下而上)的方法
  • 資料的三角測量

第3章 摘要整理

第4章 市場動態

  • 促進因素，阻礙因素，機會，課題的分析
    • 促進因素
    • 阻礙因素
    • 機會
    • 課題
  • 全球流感治療市場的COVID-19影響

第5章 市場變數與展望

  • SWOT分析
    • 優勢
    • 弱點
    • 機會
    • 威脅
  • PESTEL分析
    • 政治形勢
    • 經濟形勢
    • 社會形勢
    • 技術性形勢
    • 環境的形勢
    • 法律上的形勢
  • 波特的五力分析
    • 供給企業談判力
    • 買方議價能力
    • 替代品的威脅
    • 新加入廠商的威脅
    • 競爭企業間的敵對關係
  • 熱圖分析

第6章 競爭情形

  • 全球流感治療的製造地的分佈，銷售區域，產品類型
  • 全球流感治療市場合併和收購，夥伴關係，產品的銷售，及合作

第7章 全球流感治療市場(100萬美元)(2019年～2032年):各類型

  • 類型A
  • 類型B
  • 類型C

第8章 全球流感治療市場(100萬美元)(2019年～2032年):各藥物

  • 抗病毒藥物
  • 抗組織胺藥物
  • 止痛藥
  • 其他

第9章 全球流感治療市場(100萬美元)(2019年～2032年):各給藥途徑

  • 口服
  • 非口服
  • 其他

第10章 全球流感治療市場(100萬美元)(2019年～2032年):各流通管道

  • 醫院藥局
  • 線上藥局
  • 零售藥局

第11章 全球流感治療市場(100萬美元)(2019年～2032年):各終端用戶

  • 醫院
  • 居家醫療
  • 專門診所
  • 其他

第12章 全球流感治療市場(100萬美元)(2019年～2032年):各地區

  • 全球流感治療市場規模與市場佔有率(2019年～2025年):各地區
  • 全球流感治療市場規模與市場佔有率(2026年～2032年):各地區
  • 亞太地區
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他的亞太地區
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
    • 其他的歐洲
  • 中東和非洲
    • 沙烏地阿拉伯王國
    • 阿拉伯聯合大公國
    • 其他的中東
  • 北美
    • 加拿大
    • 墨西哥
    • 美國
  • 南美
    • 阿根廷
    • 巴西
    • 其他的南美

第13章 企業簡介

  • AstraZeneca
  • Bayer AG
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • GSK plc
  • Lilly
  • Merck & Co. Inc.
  • Mylan N.V.
  • NATCO Pharma Limited
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Sanofi

第14章 簡稱一覽

第15章 參照鏈接

第16章 結論

第17章 調查範圍

簡介目錄
Product Code: HLCA2313

Global Flu Treatment Market Overview

According to SPER Market Research, the Global Flu Treatment Market is estimated to reach USD 1.74 billion by 2032 with a CAGR of 5.25%.

Flu, commonly known as influenza, is a typical viral infection. Chills, aches in the muscles, fever, headaches, runny nose, cough, and others are common flu symptoms. The respiratory tract is primarily impacted by flu. Influenza viruses come in four main categories: influenza A, influenza B, influenza C, and influenza D. The influenza virus types A and B that cause seasonal flu most frequently each year are A and B. The market for influenza treatments has grown due to a number of causes, including an increase in healthcare spending and R&D spending on antiviral drugs. The expansion of government programmes to fight the flu and create reliable tests will support it. The rising cost of creating tests and equipment may restrain industry expansion. The limitations on accessibility and the availability of raw materials raise the cost of the final product.

Impact of COVID-19 on the Global Flu Treatment Market

The global market for flu medications is expanding as a result of ongoing advancements in technology and partnerships between private businesses and governmental agencies for the treatment of such pandemic flu. This is due to the COVID-19 disease, which is spreading continuously throughout the world and causing a significant number of deaths worldwide. Due to the global pandemic COVID-19, which has had a severe impact on a significant section of the population, the hospital pharmacies segment is predicted to exhibit the highest CAGR during the projection period. As a result, it is likely to encourage the market for flu medications to expand.

Scope of the Report:

Report Metric Details

Market size available for years 2019-2032

Base year considered 2021

Forecast period 2022-2032

Segments covered By Type, By Medication, By Route of Administration, By Distribution Channel, By End User.

Regions covered Asia-Pacific, Europe, Middle East and Africa, North America, Latin America

Companies Covered AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., GSK plc, Lilly, Merck & Co. Inc., Mylan N.V., NATCO Pharma Limited, Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd.

Global Flu Treatment Market Segmentation:

By Type: Based on the Type, Global Flu Treatment Market is segmented as; Type A, Type B, and Type C.

By Medication: Based on the Medication, Global Flu Treatment Market is segmented as; Antiviral drugs, Antihistamines, Analgesics, and Others.

By Route of Administration: Based on the Route of Administration, Global Flu Treatment Market is segmented as; Oral, Parenteral, Others

By Distribution Channel: Based on the Distribution Channel, Global Flu Treatment Market is segmented as; Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

By End User: Based on the End User, Global Flu Treatment Market is segmented as; Hospitals, Homecare, Specialty Clinics, Others

By Region: Based on region, The Global Flu Treatment Market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Due to the concentration of international players on cutting-edge technologies, the flu treatment market in North America has seen good growth over the course of the anticipated timeframe. The American healthcare authority also released COVID-19 and flu virus testing recommendations for clinicians.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global Flu Treatment Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Competitive Landscape

  • 6.1 Global Flu Treatment Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2 Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Flu Treatment Market

7. Global Flu Treatment Market, By Type, 2019-2032 (USD Million)

  • 7.1. Type A
  • 7.2. Type B
  • 7.3. Type C

8. Global Flu Treatment Market, By Medication, 2019-2032 (USD Million)

  • 8.1. Antiviral drugs
  • 8.2. Antihistamines
  • 8.3. Analgesics
  • 8.4. Others

9. Global Flu Treatment Market, By Route of Administration, 2019-2032 (USD Million)

  • 9.1. Oral
  • 9.2. Parenteral
  • 9.3. Others

10. Global Flu Treatment Market, By Distribution Channel, 2019-2032 (USD Million)

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Global Flu Treatment Market, By End User, 2019-2032 (USD Million)

  • 11.1. Hospitals
  • 11.2. Homecare
  • 11.3. Specialty Clinics
  • 11.4. Others

12. Global Flu Treatment Market, By Region, 2019-2032 (USD Million)

  • 12.1. Global Flu Treatment Market Size and Market Share by Region (2019-2025)
  • 12.2. Global Flu Treatment Market Size and Market Share by Region (2026-2032)
  • 12.3. Asia-Pacific
    • 12.3.1. Australia
    • 12.3.2. China
    • 12.3.3. India
    • 12.3.4. Japan
    • 12.3.5. South Korea
    • 12.3.6. Rest of Asia-Pacific
  • 12.4. Europe
    • 12.4.1. France
    • 12.4.2. Germany
    • 12.4.3. Italy
    • 12.4.4. Spain
    • 12.4.5. United Kingdom
    • 12.4.6. Rest of Europe
  • 12.5. Middle East and Africa
    • 12.5.1. Kingdom of Saudi Arabia
    • 12.5.2. United Arab Emirates
    • 12.5.3. Rest of Middle East & Africa
  • 12.6. North America
    • 12.6.1. Canada
    • 12.6.2. Mexico
    • 12.6.3. United States
  • 12.7. Latin America
    • 12.7.1. Argentina
    • 12.7.2. Brazil
    • 12.7.3. Rest of Latin America

13. Company Profiles

  • 13.1. AstraZeneca
    • 13.1.1. Company details
    • 13.1.2. Financial outlook
    • 13.1.3. Product summary
    • 13.1.4. Recent developments
  • 13.2. Bayer AG
    • 13.2.1. Company details
    • 13.2.2. Financial outlook
    • 13.2.3. Product summary
    • 13.2.4. Recent developments
  • 13.3. Bristol-Myers Squibb Company
    • 13.3.1. Company details
    • 13.3.2. Financial outlook
    • 13.3.3. Product summary
    • 13.3.4. Recent developments
  • 13.4. F. Hoffmann-La Roche Ltd.
    • 13.4.1. Company details
    • 13.4.2. Financial outlook
    • 13.4.3. Product summary
    • 13.4.4. Recent developments
  • 13.5. GSK plc
    • 13.5.1. Company details
    • 13.5.2. Financial outlook
    • 13.5.3. Product summary
    • 13.5.4. Recent developments
  • 13.6. Lilly
    • 13.6.1. Company details
    • 13.6.2. Financial outlook
    • 13.6.3. Product summary
    • 13.6.4. Recent developments
  • 13.7. Merck & Co. Inc.
    • 13.7.1. Company details
    • 13.7.2. Financial outlook
    • 13.7.3. Product summary
    • 13.7.4. Recent developments
  • 13.8. Mylan N.V.
    • 13.8.1. Company details
    • 13.8.2. Financial outlook
    • 13.8.3. Product summary
    • 13.8.4. Recent developments
  • 13.9. NATCO Pharma Limited
    • 13.9.1. Company details
    • 13.9.2. Financial outlook
    • 13.9.3. Product summary
    • 13.9.4. Recent developments
  • 13.10. Novartis AG
    • 13.10.1. Company details
    • 13.10.2. Financial outlook
    • 13.10.3. Product summary
    • 13.10.4. Recent developments
  • 13.11. Pfizer Inc.
    • 13.11.1. Company details
    • 13.11.2. Financial outlook
    • 13.11.3. Product summary
    • 13.11.4. Recent developments
  • 13.12. Sanofi
    • 13.12.1. Company details
    • 13.12.2. Financial outlook
    • 13.12.3. Product summary
    • 13.12.4. Recent developments
  • 13.13. Sun Pharmaceutical Industries Ltd.
    • 13.13.1. Company details
    • 13.13.2. Financial outlook
    • 13.13.3. Product summary
    • 13.13.4. Recent developments

14. List of Abbreviations

15. Reference Links

16. Conclusion

17. Research Scope